ATLANTA, GA – – (Globe Newswire – April 20, 2023) – – Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc.  (“Avidity” or the “Company”) (NASDAQ: RNA) complied with federal securities laws.  On March 30, 2023, Avidity provided an update on its product that is on a partial clinical hold for new patient enrollment by the FDA following a serious adverse event, stating that “discussions are ongoing” between the Company and the FDA and that “the Company continues to provide new data on AOC 1001 as it emerges from the MARINA Trial.” Following this disclosure, the price of the Company’s stock dropped.

If you purchased Avidity stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/avidity/ to discuss your legal rights.